DEF: Protalix BioTherapeutics Seeks Stockholder Approval for Director Elections, Executive Pay, and Auditor Ratification at 2025 Annual Meeting

Protalix BioTherapeutics is holding its 2025 Annual Meeting of Stockholders on June 26, 2025, to vote on director elections, executive compensation, and the ratification of its independent auditor.

Summary

• Protalix BioTherapeutics, Inc. will hold its 2025 Annual Meeting of Stockholders on June 26, 2025, in Tel Aviv, Israel.
• Stockholders will vote on the election or re-election of eight directors, an advisory vote on executive compensation, and the ratification of Kesselman & Kesselman as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting FOR all director nominees, FOR the advisory vote on executive compensation, and FOR the ratification of the accounting firm.
• As of April 30, 2025, there were 79,517,147 shares of common stock outstanding and entitled to vote.
• A quorum requires at least one-third (26,505,716 shares) of the outstanding shares to be present in person or represented by proxy.
• Director nominees will be elected by a plurality of votes cast.
• Approval of the advisory resolution on executive compensation and the ratification of the auditor require the affirmative vote of the majority of shares present and entitled to vote.
• Alliance Advisors LLC has been engaged to assist in soliciting proxies for a base fee of $10,000, with estimated total fees of approximately $35,000.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The company is seeking approval for routine matters, and the Board recommends voting in favor of the proposals. The sentiment is slightly positive due to the company's efforts to align executive compensation with stockholder value and maintain good corporate governance practices.

Positives

• The Board of Directors is actively engaged in risk oversight, with committees responsible for specific areas of risk management.
• The company has a Code of Business Conduct and Ethics applicable to all employees and directors.
• The company has an Insider Trading and Blackout Policy to prevent insider trading.
• The Audit and Finance Committee is comprised of independent directors and has a policy for reporting questionable accounting and auditing practices.
• The company provides stockholders with multiple avenues to communicate with the Board of Directors.

Risks

• The advisory vote on executive compensation is non-binding, meaning the Board is not obligated to act in accordance with the outcome.
• The company's success depends on attracting and retaining talented executives.
• The company operates in the biotechnology industry, which is subject to significant regulatory and clinical trial risks.

Future Outlook

The company is seeking to strengthen its pipeline of product candidates, including PRX-115, and support its commercial partners' launch efforts.

Management Comments

• We appreciate your support and look forward to your attending the meeting.

Industry Context

The company operates in the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.

Comparison to Industry Standards

• Executive compensation is benchmarked against a peer group of similar-sized biotechnology companies.
• The company uses third-party experts to analyze executive compensation and ensure competitiveness.
• The company's corporate governance practices are designed to comply with NYSE American listing requirements and the Sarbanes-Oxley Act.

Management Changes

Related Party Transactions

• During fiscal years 2023 and 2024, the company engaged Catenion for business development consulting services, the compensation for which was approximately $1.4 million in the aggregate; Christian Elze, the new director nominee, is the founder of Catenion and currently serves as a Senior Partner Emeritus of Catenion.

Stakeholder Impact

• The election of directors will impact the leadership and oversight of the company.
• The advisory vote on executive compensation allows stockholders to express their views on the company's pay practices.
• The ratification of the independent auditor ensures the integrity of the company's financial statements.

Next Steps

• Stockholders are encouraged to vote their shares via the Internet, by telephone, or by returning the proxy card.
• The company will hold its Annual Meeting of Stockholders on June 26, 2025.
• The Board of Directors and Compensation Committee will consider the outcome of the advisory vote on executive compensation when evaluating future compensation arrangements.

Key Dates

Keywords

proxy statement, annual meeting, directors, executive compensation, auditor, stockholders, corporate governance, Protalix BioTherapeutics